For Excellence in Clinical Trials Research Wednesday, May 03, 2023 CCTG is very pleased to present the Joseph Pater Founder’s Award for Excellence in Clinical Trials Research to Dr Kim Chi, a medical oncologist and the Chief Medical Officer of BC Cancer. The award is presented yearly at the Annual Spring Meeting to a clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer. “I am very honoured to have been selected for the Dr. Joseph Pater Excellence in Clinical Trials Research Award. Clinical trials are central to improving patient care and I am grateful for all the opportunities I have had to contribute to that goal. CCTG has been critical to that, connecting us across Canada and Internationally for the benefit of patients around the world. There are too many people to thank at CCTG for their mentorship and collaboration over the last 20+ years: Elizabeth Eisenhauer for her encouragement and guidance when I was a new investigator; Lesley Seymour who early on taught me the importance of rigour, process and quality; Wendy Parulekar for the years of partnership in moving trial ideas to reality; and Jean Powers who was so instrumental for the success of the early trials I had a privilege to lead. The list could go on endlessly and reflects the amazing folks that CCTG has brought together.” Kim Chi is a medical oncologist and the Chief Medical Officer of BC Cancer, which provides a comprehensive cancer control program for the people of British Columbia (BC), in Canada. He is also Professor in the Faculty of Medicine at the University of British Columbia, a Professor in the Faculty of Health Sciences at Simon Fraser University, and the Shrum Chair in Prostate Cancer Research at BC Cancer. Prof. Chi's research in the field of genitourinary cancers focuses on prostate cancer and investigational new drugs, where he has contributed to changing international standards of care practice for patients with advanced prostate cancer. He also has been investigating circulating tumour DNA as a source of prognostic and predictive biomarkers for patients with metastatic prostate cancer. Prof. Chi is the past-Chair of the Genitourinary Disease Site Committee for the Canadian Cancer Trials Group, and has held peer-reviewed grant funding from the Canada Institutes of Health Research (CIHR), National Cancer Institute of Canada (NCIC)/Canadian Cancer Society (CCS), the US Department of Defence, Movember, Prostate Cancer Foundation (USA), and Prostate Cancer Canada. Prof. Chi has published over 250 articles in prestigious peer-reviewed journals including the Journal of Clinical Oncology, Annals of Oncology, Nature, the New England Journal of Medicine, and Lancet Oncology.
